CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
GW870086 2.0% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01299610
NCT01299610Phase 2Completed
CompareCT.gov

A Randomised, Double-blind, Placebo-controlled Study of Topical GW870086X Formulation in Subjects With Moderate or Severe Atopic Dermatitis

GlaxoSmithKline·interventional·Posted Feb 18, 2011·Updated Nov 17, 2017

In Brief

A Phase 2 clinical trial evaluating GW870086 2.0%, GW870086 0.2%, and 2 other interventions for Dermatitis, Atopic. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This study is a randomised, double-blind, placebo-controlled study to assess the efficacy of GW870086X cream formulation in subjects with moderate to severe atopic dermatitis. Subjects will be assigned to take 3 out of the 4 possible treatments for 21 ±2 days: GW870086X 0.2% cream, GW870086X 2% cream, FP 0.05% cream (as a positive control) and placebo cream. All subjects will be randomised to receive placebo cream. Three index lesions located on the arms and/or legs (one on each) will be identified per subject and each treatment will be applied to the same lesion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2011
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2011
Study CompletionApr 14, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.4 years ago

Interventions

GW870086 2.0%drug

White to slightly colored opaque cream

GW870086 0.2%drug

White to slightly colored opaque cream

FP 0.05%drug

White cream

Placebodrug

White to slightly colored opaque cream